
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
The Tigerlily Foundation and Guiding Researchers and Advocates for Scientific Partnerships (GRASP) November conversation focused on what it means to have “Cancer While Black: Moving Past the Medical Mistrust Impact."
The Tigerlily Foundation and Guiding Researchers and Advocates for Scientific Partnerships (GRASP) November conversation was co-hosted by keynote speaker, Mr. Shawn Johnson, a medical student in the Pathways M.D. program at Harvard Medical School, and our patient experts, La’Kesha Jackson-Gordon, LaTayla Palmer, Tova Parker, Na’Diah Smith and Temi Omaghomi. The panelists focused on what it means to have “Cancer While Black: Moving Past the Medical Mistrust Impact.”






